Spondyloepimetaphyseal Dysplasia, Guo-Campeau Type (SEMDGC): Comprehensive Disease Characteristics Report

Summary

Spondyloepimetaphyseal Dysplasia, Guo-Campeau type (SEMDGC; OMIM #620663; MONDO:0958006) is an ultra-rare autosomal-recessive Mendelian skeletal dysplasia caused by biallelic missense variants in the ERI1 gene (chromosome 8p23.1; OMIM 608739; HGNC:23994). ERI1 encodes a highly conserved DEDDh-family 3′→5′ exoribonuclease that carries out two essential RNA-metabolic functions: 3′-end maturation of the 5.8S ribosomal RNA (ribosome biogenesis) and degradation of replication-dependent histone mRNAs (cell-cycle-coupled histone homeostasis). The disease was defined by Guo et al. in 2023 (American Journal of Human Genetics*) in a landmark cohort of 8 affected individuals from 7 unrelated families and has since been reviewed comprehensively (2025).

The defining scientific feature of this disorder is a striking genotype–phenotype dichotomy: individuals carrying at least one missense variant develop the severe skeletal dysplasia (SEMDGC), whereas individuals with biallelic null (nonsense) variants present only with mild intellectual disability and digital anomalies — a distinct, milder allelic condition now designated Hoxha-Aliu syndrome (HXAL; OMIM #620662). This inverse relationship — where the "milder" molecular lesion (missense) produces the more severe clinical phenotype — strongly implies a dominant-negative or neomorphic (gain-of-toxic-function) mechanism of the catalytically dead protein, rather than simple loss-of-function haploinsufficiency. Functionally, the pathogenic missense variants cluster in the C-terminal exonuclease (EXOIII/DEDDh) domain, abolish 3′→5′ exoribonuclease activity, and fail to rescue 5.8S rRNA processing defects in ERI1-knockout cells.

The clinical phenotype spans a broad severity spectrum, from survival into adulthood to infantile/early-childhood lethality (deaths at 4 months, 5 months, and 2 years documented in the founding cohort). Core features include severe short stature, platyspondyly with irregular vertebral endplates, scoliosis, epiphyseal/metaphyseal dysplasia, facial dysmorphism, and dysplastic-to-absent digits. Patient-derived iPSCs show impaired in vitro chondrogenesis with downregulation of skeletal-patterning genes, providing the cellular link between RNA-metabolic dysfunction and the skeletal phenotype. No curative therapy exists; management is supportive and orthopedic. Eri1-knockout mice only partially recapitulate the disease (growth restriction and brachydactyly, but not SEMD), and notably resemble the human null-allele (Hoxha-Aliu) phenotype rather than the missense-driven SEMDGC.

Section 1: Disease Information

Overview

SEMDGC is a congenital, autosomal-recessive skeletal dysplasia belonging to the spondyloepimetaphyseal dysplasia (SEMD) group — disorders affecting the spine (spondylo-), the epiphyses (epi-), and the metaphyses (-metaphyseal) of the long bones. It is caused by biallelic pathogenic variants in ERI1, a gene central to RNA metabolism. The disorder is characterized by severe growth failure, vertebral and long-bone abnormalities, and hand/foot malformations, often accompanied by facial dysmorphism and, in a subset, extraskeletal (renal, cardiac) anomalies and developmental delay.

Key Identifiers

Synonyms / Alternative Names

• Spondyloepimetaphyseal dysplasia, Guo-Campeau type
• SEMDGC
• SEMD Guo-Campeau type
• ERI1-related spondyloepimetaphyseal dysplasia

Information Source

Information is derived from aggregated disease-level resources (OMIM, MONDO, UniProt) and individual-patient case reports aggregated into the founding cohort study of 8 individuals from 7 families (PMID: 37352860) plus a 2025 review (PMID: 39945916). It is not derived from large-scale EHR datasets — appropriately, given the ultra-rare nature of the condition.

Section 2: Etiology

Disease Causal Factors

The disease is entirely genetic (Mendelian, monogenic, autosomal recessive). There are no known environmental, infectious, or mechanical causes. The cause is biallelic missense variants in ERI1, with a requirement that at least one allele be a missense variant to produce the severe SEMD phenotype.

Genetic Risk Factors

• Causal variants: Biallelic ERI1 variants; specifically, at least one missense variant in the C-terminal exonuclease domain is required for the severe SEMDGC phenotype.
• Genotype–phenotype relationship (the central etiologic insight): "A severe spondyloepimetaphyseal dysplasia (SEMD) was identified in five affected individuals with missense variants but not in those with bi-allelic null variants, who showed mild intellectual disability and digital anomalies" (PMID: 37352860).
• Susceptibility loci / modifier genes: None established. Given the monogenic, highly penetrant nature, classical susceptibility loci are not applicable.

Environmental / Lifestyle Risk Factors

None known or applicable. As a Mendelian congenital disorder, environmental exposures, lifestyle, occupational factors, age, and sex are not established contributors to disease occurrence. Consanguinity is relevant as it increases the likelihood of biallelic (homozygous) recessive variants (see Section 9).

Protective Factors

No genetic or environmental protective factors are established. Theoretically, the null-allele end of the allelic series is "protective" against the severe skeletal phenotype in the sense that biallelic nulls do NOT produce SEMD — but this reflects the neomorphic biology of the missense protein rather than a conventional protective factor.

Gene–Environment Interactions

None documented. The disorder is deterministic and genetic.

Section 3: Phenotypes

The phenotype is congenital in onset and, in the severe (missense) form, ranges from moderate to lethal. The following table catalogs the reported phenotypes with suggested HPO terms.

Phenotype Characteristics

• Age of onset: Congenital / neonatal (skeletal dysplasia present from birth).
• Severity: Variable — from survival into adulthood to infantile lethality. Severity tracks with genotype (missense → severe; null → mild).
• Progression: Skeletal features (e.g., scoliosis) are progressive with age; overall the disorder is chronic and lifelong in survivors.
• Frequency among affected: In the founding cohort, severe SEMD occurred in 5 of 8 affected individuals (all carrying ≥1 missense variant); the remaining individuals (biallelic null) had only mild ID and digital anomalies.

Quality of Life Impact

Severe short stature, skeletal deformity (scoliosis, joint/limb abnormalities), and digital malformations substantially impair mobility, dexterity, and daily functioning. In the lethal subset, infants die in early childhood. Disease-specific QoL instruments (EQ-5D, SF-36) have not been applied to this ultra-rare condition; QoL impact is inferred from phenotype severity.

Section 4: Genetic / Molecular Information

Causal Gene

• Gene: ERI1 (Exoribonuclease 1); OMIM *608739; HGNC:23994; NCBI Gene 90459; Ensembl ENSG00000104626.
• Aliases: 3′HEXO, THEX1, HEXO.
• Locus: 8p23.1.
• Protein: UniProt Q8IV48 — a DEDDh-superfamily 3′→5′ exonuclease with an N-terminal SAP (RNA-binding) domain and a C-terminal EXOIII/DEDDh catalytic exonuclease domain.

Pathogenic Variants

The SEMDGC-causing missense variants cluster in the C-terminal 3′ exonuclease (EXOIII/DEDDh) domain, sparing the N-terminal SAP RNA-binding domain.

• Variant classification: Pathogenic (functionally validated).
• Variant types: Missense (SEMDGC); nonsense/null (Hoxha-Aliu syndrome).
• Somatic vs germline: Germline.
• Functional consequences: The missense variants cause loss of exoribonuclease catalytic activity. Critically, in ERI1-knockout HeLa cells, the defective 5.8S rRNA processing was rescued by wild-type ERI1 but NOT by the D298A or P155L mutants — confirming loss-of-catalytic-function at the enzymatic level. However, because biallelic null variants produce a milder phenotype, the missense proteins are inferred to act via a dominant-negative/neomorphic mechanism (the catalytically dead but still-expressed protein interferes beyond simple loss of function).

Direct evidence: "The ERI1 missense variants cause a loss of the exoribonuclease activity, leading to defective trimming of the 5.8S rRNA 3′ end and a decreased degradation of replication-dependent histone mRNAs." (PMID: 37352860).

Modifier Genes

None established.

Epigenetic Information

No disease-specific DNA methylation or histone-modification changes have been reported for SEMDGC itself. Of note, ERI1 participates in heterochromatin formation and RNA interference in model organisms, but a direct epigenetic disease mechanism in humans has not been demonstrated.

Chromosomal Abnormalities

None. SEMDGC is caused by point mutations, not large-scale structural/chromosomal changes.

Section 5: Environmental Information

• Environmental factors: None. Not applicable to this monogenic disorder.
• Lifestyle factors: None applicable.
• Infectious agents: None. This is not an infectious or trigger-mediated disease.

This section is not applicable to SEMDGC beyond noting the deterministic genetic etiology.

Section 6: Mechanism / Pathophysiology

Causal Chain Overview

Biallelic ERI1 missense variant (≥1 allele)
│  (C-terminal DEDDh exonuclease domain)
▼
Loss of 3′→5′ exoribonuclease catalytic activity
   (dominant-negative / neomorphic — worse than null)
│
├──► Defective 3′-end trimming of 5.8S rRNA
│        → impaired ribosome biogenesis (ribosomopathy-like)
│
└──► Decreased degradation of replication-dependent histone mRNAs
         → accumulation of oligouridylated histone mRNAs;
           dysregulated cell-cycle-coupled histone supply
│
▼
Impaired chondrocyte differentiation (defective chondrogenesis)
   + downregulation of skeletal-patterning genes
│
▼
Abnormal growth-plate function
│
▼
Spondyloepimetaphyseal dysplasia: short stature, platyspondyly,
epi-/metaphyseal dysplasia, digital anomalies

Molecular Pathways

ERI1 is not part of a classical signaling cascade (Wnt, MAPK, etc.) but operates in two core RNA-metabolic pathways: 1. Ribosome biogenesis — 5.8S rRNA 3′-end maturation. "Eri1 is an evolutionarily conserved 3′-5′ exoribonuclease that participates in 5.8S rRNA 3′ end processing and turnover of replication-dependent histone mRNAs" (PMID: 24929628). 2. Replication-dependent histone mRNA turnover — ERI1 degrades the 3′ stem-loop of oligouridylated histone mRNAs to trigger replication-dependent decay. "Both processes are impaired in Eri1-deficient mouse cells, which instead accumulate oligouridylated histone mRNAs" (PMID: 23202588).

The 2025 review summarizes ERI1's multifunctional role: "including modulating RNA interference, heterochromatin formation, rRNA maturation, and histone mRNA degradation" (PMID: 39945916).

Cellular Processes

The convergent cellular phenotype is impaired chondrogenesis. Patient iPSC-derived chondrocytes: "Affected-individual-derived induced pluripotent stem cells (iPSCs) showed impaired in vitro chondrogenesis with downregulation of genes regulating skeletal patterning" (PMID: 37352860). Because ribosome biogenesis and histone-mRNA supply are both essential for the rapid, tightly cell-cycle-coupled proliferation of growth-plate chondrocytes, this cell type is particularly vulnerable — consistent with the ribosomopathy paradigm in which defects in housekeeping RNA machinery produce tissue-selective (often skeletal) phenotypes.

Protein Dysfunction

The pathogenic missense substitutions in the C-terminal DEDDh catalytic domain abolish exonuclease activity while (presumably) preserving expression and RNA-binding via the intact N-terminal SAP domain. This is the structural basis for a dominant-negative effect: a stable but catalytically dead enzyme that can still engage substrates/complexes and thereby interfere with residual function — explaining why missense is worse than null.

Metabolic / Immune / Tissue-Damage Mechanisms

• Metabolic changes: Not a classical metabolic disorder; the "metabolism" affected is RNA metabolism.
• Immune involvement: Not established as a primary driver, though ERI1 has roles in RNA interference/innate nucleic-acid handling in model systems.
• Tissue damage mechanism: Developmental — failure of proper chondrocyte differentiation and growth-plate function rather than degenerative injury.

Suggested Ontology Terms

• GO (biological process): rRNA processing (GO:0006364); ribosomal large subunit biogenesis (GO:0042273); histone mRNA catabolic process (GO:0071044); chondrocyte differentiation (GO:0002062); skeletal system development (GO:0001501).
• GO (molecular function): 3′-5′ exoribonuclease activity (GO:0000175); rRNA binding.
• GO (cellular component): cytoplasm (GO:0005737); nucleolus (GO:0005730).
• CL (cell types): chondrocyte (CL:0000138); growth plate chondrocyte.

Section 7: Anatomical Structures Affected

Organ Level

• Primary: Skeletal system — vertebral column (spine), epiphyses and metaphyses of long bones, hands and feet (digits), skull/craniofacial bones.
• Secondary / extraskeletal (subset of severe patients): Kidneys (renal anomalies), heart (cardiac anomalies), central nervous system (developmental delay/intellectual disability).
• Body systems: Musculoskeletal (primary); renal, cardiovascular, and nervous systems (secondary, variable).

Tissue and Cell Level

• Tissue: Cartilage / growth-plate cartilage (connective tissue); bone.
• Cell populations: Chondrocytes, particularly growth-plate chondrocytes (CL:0000138). Chondrocyte differentiation from mesenchymal/iPSC-derived precursors is the demonstrated point of failure.

Subcellular Level

• Compartments: Nucleolus (GO:0005730) — site of rRNA processing; cytoplasm (GO:0005737) — histone mRNA turnover. ERI1's activity spans nucleolar (ribosome biogenesis) and cytoplasmic (histone mRNA decay) compartments.

Localization

• Anatomical sites (UBERON): vertebral column (UBERON:0001130); epiphysis (UBERON:0002515); metaphysis (UBERON:0004417); manus/digits (UBERON:0002398); growth plate (UBERON:0006611); skull (UBERON:0003129).
• Lateralization: Bilateral and generally symmetric (as typical for generalized skeletal dysplasias).

Section 8: Temporal Development

Onset

• Age of onset: Congenital / prenatal-neonatal. The skeletal dysplasia is present at birth; some features detectable prenatally.
• Onset pattern: Chronic/congenital (present from development).

Progression

• Stages: No formal staging system exists. Skeletal features such as scoliosis progress with growth.
• Progression rate: Variable — correlates with genotype and residual function.
• Course pattern: Progressive (skeletal deformities) but non-episodic.
• Duration: Lifelong in survivors; lethal in a subset during infancy/early childhood.

Patterns

• Severity spectrum (documented): In the founding cohort, family 1 comprised a 28-year-old woman and her 26-year-old brother (survival into adulthood), whereas families 2, 3, and 4 had children who died at 4 months, 5 months, and 2 years of age, respectively — demonstrating infantile/early-childhood lethality in a subset.
• Critical periods: Fetal and early-postnatal growth-plate development is the window of vulnerability; there is no known intervention window given the developmental, genetic nature.
• Remission: None; this is a structural, developmental disorder without remission.

Section 9: Inheritance and Population

Epidemiology

• Prevalence / incidence: Ultra-rare; no formal prevalence or incidence estimates. Fewer than 10 individuals reported worldwide (8 affected individuals from 7 families in the founding cohort). Too rare for population registry quantification.

Genetic Etiology

• Inheritance pattern: Autosomal recessive (biallelic ERI1 variants required).
• Penetrance: Complete for the biochemical/skeletal phenotype given the appropriate genotype; genotype-dependent expressivity determines whether severe SEMD (≥1 missense) or mild Hoxha-Aliu (biallelic null) results.
• Expressivity: Highly variable within the severe form — from adult survival to infantile lethality.
• Genetic anticipation: Not applicable (not a repeat-expansion disorder).
• Germline mosaicism: Not reported.
• Founder effects: None established.
• Consanguinity: Relevant — recessive inheritance means consanguineous unions increase risk of homozygous biallelic variants (e.g., the homozygous K118X in the Nepali Hoxha-Aliu patient).
• Carrier frequency: Not established; expected to be very low given rarity. P155L allele frequency <0.0001 in gnomAD/ExAC; D298A absent from population databases.

Population Demographics

• Affected populations: No specific ethnic predisposition; families reported are geographically/ethnically diverse.
• Geographic distribution: Global, sporadic; no endemic clustering.
• Sex ratio: No sex bias expected (autosomal); cohort included both sexes.
• Age distribution: Congenital-onset; affected individuals range from infants to adults (in survivors).

Section 10: Diagnostics

Clinical Tests

• Imaging (central to diagnosis): Skeletal survey / radiography (X-ray) revealing platyspondyly (HP:0000926), irregular vertebral endplates (HP:0003417), epiphyseal and metaphyseal dysplasia, scoliosis, and digital anomalies. Radiographic pattern recognition is the first-line diagnostic modality for skeletal dysplasias.
• Laboratory tests: No specific biochemical marker; biochemical tests (e.g., for mucopolysaccharidoses) are used to exclude differential diagnoses.
• Biomarkers: None validated (no circulating protein/metabolite biomarker).
• Biopsy/pathology: Not routinely used; cartilage histology may show abnormal chondrocyte organization but is not standard.

Genetic Testing (definitive)

• Recommended approach: Molecular confirmation of biallelic ERI1 variants via sequencing.
• WES / WGS: High utility — exome or genome sequencing is the primary route to diagnosis, especially given the rarity and the need to detect two variants in ERI1. GeneMatcher-type data sharing was instrumental in defining the cohort.
• Gene panels: Skeletal dysplasia / SEMD gene panels including ERI1.
• Single-gene testing: Targeted ERI1 sequencing when the phenotype is recognized.
• CMA / karyotype / FISH / mtDNA / repeat expansion: Not indicated (point-mutation disorder).

Omics-Based Diagnostics

• Functional/research assays: iPSC-derived chondrogenesis and 5.8S rRNA processing/histone mRNA turnover assays can confirm variant pathogenicity but are research tools, not clinical diagnostics.

Clinical Criteria & Differential Diagnosis

• Diagnostic criteria: Combination of characteristic radiographic SEMD pattern + biallelic ERI1 variants (≥1 missense for the severe form).
• Differential diagnosis: Other spondyloepimetaphyseal dysplasias and skeletal dysplasias, including:
• Dyggve-Melchior-Clausen (DMC) syndrome — AR SEMD with platyspondyly, rhizomelic shortening, metaphyseal dysplasia; overlaps with MPS IV; caused by DYM variants (PMID: 41549465).
• SEMD with joint laxity, leptodactylic (Hall) type — short stature, midface hypoplasia, joint dislocations/laxity, metaphyseal vertical striations (PMID: 19277648).
• Mucopolysaccharidosis type IV (Morquio) — excluded by urine GAG / enzyme testing.
• Genetic testing distinguishes SEMDGC from these phenocopies.

Screening

• Cascade / carrier screening: Offered to relatives once a familial variant is identified.
• Prenatal testing: Available for at-risk pregnancies via targeted variant testing.
• Newborn screening: Not part of any newborn screening program.

Section 11: Outcome / Prognosis

Survival and Mortality

• Life expectancy: Highly variable and genotype/severity-dependent. Documented outcomes range from survival into adulthood (28- and 26-year-old sibs, family 1) to early death (4 months, 5 months, 2 years in families 2–4).
• Mortality: A significant subset of severe (missense) SEMDGC is infantile/early-childhood lethal. The milder null-allele (Hoxha-Aliu) form is not lethal.

Morbidity and Function

• Survivors face substantial morbidity: severe short stature, skeletal deformity/scoliosis, digital malformations, and (in some) intellectual disability and extraskeletal (renal/cardiac) complications, all impairing mobility, dexterity, and independence.
• Formal disability/QoL metrics have not been reported for this ultra-rare disease.

Disease Course & Complications

• Complications include progressive scoliosis, joint/limb deformity, and — in severely affected infants — the systemic consequences that lead to early death (potentially compounded by renal/cardiac anomalies).
• Recovery potential: none; the disorder is structural and developmental, without curative options.

Prognostic Factors

• Genotype is the key prognostic factor: missense (≥1 allele) → severe SEMD, potentially lethal; biallelic null → mild phenotype (Hoxha-Aliu).
• No validated prognostic biomarkers beyond genotype.

Section 12: Treatment

There is no curative or disease-modifying therapy for SEMDGC. Management is supportive and multidisciplinary.

Pharmacotherapy

• No approved pharmacotherapy targets the underlying RNA-metabolic defect. Symptomatic management (e.g., analgesia for musculoskeletal pain) as needed.
• Pharmacogenomics: Not applicable.

Advanced Therapeutics

• Gene therapy / gene editing, RNA-based, cell, immuno-, targeted therapies: None available or in trials for SEMDGC. The dominant-negative/neomorphic mechanism suggests that allele-specific silencing (e.g., ASO/siRNA against the mutant allele) is a theoretically rational future strategy, but this is purely conceptual at present.

Surgical and Interventional

• Orthopedic surgery for scoliosis and limb/joint deformities as clinically indicated (NCIT: Orthopedic Surgical Procedure).

Supportive and Rehabilitative

• Physical therapy, occupational therapy, orthotics, and mobility aids to optimize function (NCIT: Physical Therapy, Occupational Therapy).
• Management of extraskeletal complications (renal, cardiac) per subspecialty guidelines when present.

Experimental

• No registered clinical trials specific to SEMDGC (ultra-rare condition).

Treatment Strategy

• Supportive, symptom-directed, multidisciplinary care coordinated by clinical genetics, orthopedics, and relevant subspecialties.
• Suggested NCIT concepts: Supportive Care; Physical Therapy; Orthopedic Surgery; Genetic Counseling.

Section 13: Prevention

Prevention Levels

• Primary prevention: Not possible for occurrence in a conceived affected individual (genetic, congenital). Prevention is achieved at the reproductive level via genetic counseling and reproductive options.
• Secondary prevention: Early diagnosis (radiographic + genetic) to enable timely supportive/orthopedic management and surveillance for extraskeletal complications.
• Tertiary prevention: Management to prevent/limit complications (scoliosis progression, joint deformity).

Genetic Screening & Counseling

• Genetic counseling is central: for autosomal-recessive inheritance, unaffected carrier parents have a 25% recurrence risk per pregnancy.
• Carrier / cascade screening for at-risk relatives once the familial variants are known.
• Prenatal diagnosis and preimplantation genetic testing (PGT) are options for families with known biallelic variants.
• Consanguinity counseling is relevant in affected/at-risk families.

Immunization / Public Health / Environmental / Behavioral

• Not applicable — no infectious, environmental, or behavioral component.

Section 14: Other Species / Natural Disease

Taxonomy & Orthologs

ERI1 is highly evolutionarily conserved. Orthologs (with NCBI Gene where noted):

Natural Disease in Other Species

• No naturally occurring SEMDGC-equivalent disease has been reported in companion animals or wildlife (OMIA lists no established natural ERI1 skeletal-dysplasia phenotype).

Comparative Biology

• The 3′→5′ exoribonuclease function and its roles in 5.8S rRNA processing and histone mRNA turnover are evolutionarily conserved from C. elegans to humans, underscoring that these functions are ancient and essential. Functional conservation of ERI1's roles across human cells and the mouse ortholog was demonstrated by Guo et al. 2023.

Transmission

• Not applicable (non-infectious genetic disorder; no zoonotic potential).

Section 15: Model Organisms

Available Models

Model Characteristics & Limitations

• Mouse KO: "Although Eri1 knockout (KO) mice showed mild skeletal phenotypes, neither SEMD nor digital anomaly were found" (PMID: 39945916). X-ray/histology showed reduced body size and brachydactyly but no clear epimetaphyseal changes; the mild platyspondyly was attributed to small body size. The authors concluded the KO phenotype resembles human null-variant (Hoxha-Aliu) patients rather than the missense (SEMDGC) patients — an important caveat: a knockout does not model a dominant-negative missense disorder. A knock-in of the missense allele would be the appropriate model.
• iPSC model: Reproduces impaired chondrocyte differentiation — the most disease-relevant human cellular readout.

Applications & Resources

• Models enable study of RNA-metabolic function (rRNA/histone mRNA), chondrogenesis, and variant pathogenicity.
• Resources: MGI (mouse Eri1, MGI:1914526), ZFIN (zebrafish eri1), Cellosaurus/patient iPSC lines.

Mechanistic Model / Interpretation

SEMDGC is best understood as a ribosomopathy-like RNA-metabolic disorder with a neomorphic twist. The central, non-obvious insight is the inverse genotype–phenotype relationship:

Molecular severity:   NULL (nonsense)   <   MISSENSE (catalytically dead but stable)
Clinical severity:    MILD (Hoxha-Aliu) <   SEVERE (SEMDGC, sometimes lethal)

A simple loss-of-function model would predict that null alleles (which remove the protein entirely) should be at least as severe as missense alleles. The opposite is observed, which is the signature of a dominant-negative or neomorphic (gain-of-toxic-function) mechanism: the missense proteins retain expression and likely RNA-binding (intact N-terminal SAP domain) but lack catalysis (mutated C-terminal DEDDh domain), allowing them to occupy substrates or complexes non-productively and interfere with residual RNA-processing capacity beyond mere absence of the enzyme.

Downstream, the loss of ERI1 catalytic function corrupts two housekeeping RNA pathways — 5.8S rRNA 3′-end maturation (ribosome biogenesis) and replication-dependent histone mRNA decay (cell-cycle-coupled histone homeostasis). Both are indispensable for the intense proliferative and biosynthetic demands of growth-plate chondrocytes, explaining the tissue-selective skeletal phenotype despite the ubiquitous expression of ERI1. The patient iPSC data — impaired chondrogenesis with downregulated skeletal-patterning genes — provide the empirical bridge from RNA machinery to bone.

This model is corroborated by the mouse: because the KO removes the protein (mimicking the human null/Hoxha-Aliu allele), it produces only the mild phenotype and fails to reproduce SEMD — exactly as the neomorphic model predicts.

Allelic Series Summary

(Note: A "renal hypodysplasia/aplasia 3, #617805" association listed by some aggregators (GeneCards) is a curation artifact and is NOT an established ERI1 disorder. Renal and cardiac anomalies with developmental delay were, however, observed as features in one severe SEMDGC patient — family 4.)

Evidence Base

Key supporting quotes: - Genotype–phenotype dichotomy: "A severe spondyloepimetaphyseal dysplasia (SEMD) was identified in five affected individuals with missense variants but not in those with bi-allelic null variants, who showed mild intellectual disability and digital anomalies" (PMID: 37352860). - Enzymatic/RNA consequence: "The ERI1 missense variants cause a loss of the exoribonuclease activity, leading to defective trimming of the 5.8S rRNA 3′ end and a decreased degradation of replication-dependent histone mRNAs" (PMID: 37352860). - Cellular mechanism: "Affected-individual-derived induced pluripotent stem cells (iPSCs) showed impaired in vitro chondrogenesis with downregulation of genes regulating skeletal patterning" (PMID: 37352860). - Normal ERI1 function: "Eri1 is an evolutionarily conserved 3′-5′ exoribonuclease that participates in 5.8S rRNA 3′ end processing and turnover of replication-dependent histone mRNAs" (PMID: 24929628). - Histone mRNA arm: "Both processes are impaired in Eri1-deficient mouse cells, which instead accumulate oligouridylated histone mRNAs" (PMID: 23202588). - ERI1 multifunctionality: "including modulating RNA interference, heterochromatin formation, rRNA maturation, and histone mRNA degradation" (PMID: 39945916). - Model limitation: "Although Eri1 knockout (KO) mice showed mild skeletal phenotypes, neither SEMD nor digital anomaly were found" (PMID: 39945916).

Evidence source types: human clinical/genetic (cohort and case reports), in vitro (iPSC-derived chondrocytes, HeLa rescue assays, enzymatic activity), and model organism (mouse, zebrafish, C. elegans).

Limitations and Knowledge Gaps

1. Ultra-small evidence base. The disease is defined by a single cohort (8 individuals/7 families) plus one review. Epidemiological parameters (prevalence, incidence, carrier frequency, sex ratio) are unknown.
2. Mechanism not fully resolved. The dominant-negative/neomorphic model is strongly inferred from the inverse genotype–phenotype relationship and rescue assays, but the precise molecular mechanism by which the catalytically dead protein produces a worse phenotype than its absence has not been directly demonstrated (e.g., no structural or interactome study of the mutant protein interfering with a complex).
3. No missense knock-in animal model. The existing Eri1-KO mouse models the null (Hoxha-Aliu) end, not SEMDGC. A knock-in of a patient missense allele is needed to faithfully model the severe disease.
4. Extraskeletal phenotype incompletely characterized. Renal, cardiac, and neurodevelopmental features were noted in only a subset (family 4) and their penetrance/mechanism are unclear.
5. Genotype–phenotype granularity. Which specific missense residues correlate with lethal vs adult-survival outcomes is not established; the sample is too small.
6. Epigenetic and multi-omic data absent. No methylation, proteomic, or metabolomic profiling of patient tissues exists.
7. Database curation artifact. The "renal hypodysplasia/aplasia 3" (RHDA3, #617805) association listed by some aggregators (GeneCards) is NOT a validated ERI1 disorder — only SEMDGC (#620663) and Hoxha-Aliu syndrome (#620662) are established ERI1 phenotypes.

Proposed Follow-up Experiments / Actions

1. Generate a missense knock-in mouse (e.g., Eri1 D298A or P155L) to test whether the missense allele — unlike the KO — recapitulates severe SEMD, directly validating the neomorphic model.
2. Biochemically dissect the dominant-negative mechanism: compare mutant vs WT ERI1 in substrate binding, complex incorporation, and competition assays; determine whether mutant protein sequesters substrates/partners.
3. Deep-phenotype and expand the cohort via international data sharing (GeneMatcher, Matchmaker Exchange) to define penetrance of extraskeletal features and refine residue-level genotype–phenotype correlations.
4. Multi-omic profiling of patient iPSC-chondrocytes: RNA-seq (skeletal-patterning gene networks), ribosome profiling (translational impact of 5.8S rRNA defect), and histone mRNA/protein quantification to map the causal chain quantitatively.
5. Test allele-selective therapeutic concepts in vitro: ASO/siRNA knockdown of the mutant allele in patient iPSC-chondrocytes to determine whether removing the dominant-negative protein rescues chondrogenesis — a proof-of-concept for future therapy.
6. Correct database curation: flag the erroneous RHDA3/#617805–ERI1 association and ensure knowledge bases list only SEMDGC (#620663) and Hoxha-Aliu syndrome (#620662).
7. Establish natural-history surveillance guidance: given the lethal subset, define recommended monitoring (renal, cardiac, spinal/scoliosis) for diagnosed infants.

Report compiled from a 5-iteration autonomous investigation. Evidence types: human clinical (cohort/case reports), in vitro (iPSC-chondrocytes, HeLa rescue assays), and model organism (mouse, zebrafish, C. elegans). All mechanistic and clinical claims are attributed to the cited primary literature and review as indicated.

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• MONDO:0958006 (2 mentions) - the report calls it "MONDO"; MONDO calls it spondyloepimetaphyseal dysplasia, Guo-Campeau type
• HP:0003510 (1 mention) - the report calls it "Physical/growth"; HP calls it Severe short stature
• HP:0000926 (2 mentions) - the report calls it "Skeletal/radiographic"; HP calls it Platyspondyly
• HP:0003417 (2 mentions) - the report calls it "Radiographic"; HP calls it Coronal cleft vertebrae
• HP:0002650 (1 mention) - the report calls it "Skeletal"; HP calls it Scoliosis
• HP:0030084 (1 mention) - the report calls it "Digital"; HP calls it Clinodactyly
• HP:0012385 (1 mention) - the report calls it "Digital"; HP calls it Camptodactyly
• HP:0001159 (1 mention) - the report calls it "Digital"; HP calls it Syndactyly
• HP:0000268 (1 mention) - the report calls it "Craniofacial"; HP calls it Dolichocephaly
• HP:0000243 (1 mention) - the report calls it "Craniofacial"; HP calls it Trigonocephaly
• HP:0001256 (1 mention) - the report calls it "Neurodevelopmental"; HP calls it Mild intellectual disability
• CL:0000138 (2 mentions) - the report calls it "growth-plate chondrocytes", "Cell populations: Chondrocytes, particularly growth-plate chondrocytes"; CL calls it chondrocyte

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0001263 (1 mention) - the report calls it "Neurodevelopmental"; HP calls it Global developmental delay, and lists "Developmental delay" among its other names
• GO:0005730 (2 mentions) - the report calls it "Compartments: Nucleolus"; GO calls it nucleolus**

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• CL:0000138 - called "growth-plate chondrocytes", "Cell populations: Chondrocytes, particularly growth-plate chondrocytes"

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: MGI.